DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1575)

Ovarian Cancer - 2013

Last Updated 2 December 2013
Bevacizumab (Roche/Genentech/Chugai’s Avastin) is the only targeted agent approved for ovarian cancer (CaO). We anticipate robust growth in the CaO market over our forecast period owing to penetration of bevacizumab in nearly all segments of the CaO market and the entry of premium-priced targeted therapies, some from novel drug classes. Oncologists are enthusiastic in welcoming new market entrants offering increased improved efficacy and tolerability into their treatment armamentarium. With the number of targeted agents approved for CaO set to increase significantly over the forecast period, determining the optimal sequential treatment to ensure the greatest patient benefit will be a key challenge.

Questions Answered in This Report:

  • We forecast that the CaO market will more than double in size over the 2012-2022 forecast period. What are the key drivers of this market growth? What will be the major constrainers countering this market growth? What are the drug development activities of note? What challenges and opportunities remain?

  • Bevacizumab received European approval for first-line advanced CaO in December 2011 and represents the first targeted drug to be approved for the disease. To what extent has bevacizumab penetrated the CaO market in Europe? Will bevacizumab receive approval in the first-line setting in other markets? Will bevacizumab successfully penetrate recurrent market settings?

  • Angiogenesis is now regarded as a well-validated concept in both CaO tumorigenesis and drug targeting for the disease. Will any other angiogenesis inhibitors launch during the 2012-2022 forecast period? How many launches are anticipated in this drug class? What differentiates the various emerging therapies in this drug class?

  • Agents are in late-stage development from two novel drug classes in CaO. What novel agents are expected to launch within the 2012-2022 forecast period? How will they compete with the well validated angiogenesis inhibitor drug class? In what patient populations will they be used? What are interviewed experts’ opinions of these novel drug classes?

  • Most CaO patients are still treated by chemotherapy and an unmet need exists for more-active and tailored therapies in all treatment settings and for specific CaO histologies. Is this unmet need likely to be met over the forecast period? What treatment setting is the most underserved, or has the largest opportunity? What clinical trial design hurdles face drug developers in CaO? What are the key clinical trial end points according to interviewed experts?

Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 29 country-specific interviews with experts; physician surveys fielded to approximately 30 physicians from each of the major markets who treat at least five CaO patients per month.

Epidemiology: Diagnosed Incident cases of epithelial ovarian cancer by stage at diagnosis (I-IIA, IIB-IIC, III, and IV).

Population segments in market forecast: Early-stage first-line, advanced-stage first-line, second-line platinum-sensitive, second-line platinum-resistant, third-line, fourth and subsequent lines.

Emerging therapies: Phase II: 23 drugs; Phase III: 10 drugs.

Market forecast features: Using a proprietary patient-flow model incorporating mortality, we forecast population sizes and drug sales for all patient segments through 2022.

Alternative market scenarios: (1) If emerging targeted agents and bevacizumab receive regulatory approval in the first-line advanced CaO setting in the United States (2) If therapies from a novel drug class in CaO disappoint in their Phase III trials and fail to gain regulatory approval in any market under study.